Enterprise Value
4.795B
Cash
827M
Avg Qtr Burn
-80.12M
Short % of Float
10.72%
Insider Ownership
17.56%
Institutional Own.
88.81%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tavapadon Details Parkinson's disease, Brain disease | Phase 3 Data readout | |
Tavapadon (adjunct with L-Dopa) Details Parkinson's disease, Brain disease | Phase 3 Data readout | |
Phase 2 Data readout | ||
Darigabat (CVL-865) Details Epilepsy | Phase 2 Data readout | |
Emraclidine (CVL-231) Details Brain disease, Schizophrenia | Phase 2 Data readout | |
Darigabat Details Social Anxiety Disorder | Phase 2 Initiation | |
CVL-354 Details Major depressive disorder | Phase 1 Data readout |